Journal
JOURNAL OF CROHNS & COLITIS
Volume 17, Issue 6, Pages 995-1009Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjad005
Keywords
Inflammatory bowel disease; vaccine; pregnancy; newborn; in utero; breastfeeding; biologic
Categories
Ask authors/readers for more resources
Infants exposed to biological drugs in utero have adequate serological responses to vaccines, and there are no relevant adverse events for non-live inactivated vaccines. Live-attenuated vaccines should be avoided in children with detectable levels of biological drugs. Breastfeeding by mothers treated with biologics is considered safe for infants, and the benefits of breastfeeding while receiving treatment and adhering to infant immunization programs outweigh any potential risk.
Background Biological agents cross the placenta, resulting in detectable blood levels in the neonate. Neonatal vaccinations are essential to prevent serious infections. Aim To review the effectiveness and safety of vaccines in children exposed to biological drugs in utero and/or those whose mothers received biological agents during lactation. Methods A systematic bibliographic search was performed. Results Infants exposed in utero to anti-tumour necrosis factor drugs [anti-TNFs], vedolizumab or ustekinumab mount adequate serological responses to vaccines. No relevant adverse events for non-live inactivated vaccines have been reported in newborns exposed in utero to biologics. Studies assessing the safety of live-attenuated vaccines administered to infants exposed to biologics in utero have not observed, in general, serious adverse events. However, although no severe complications have been reported with rotavirus live vaccination, several fatal disseminated tuberculosis infections after administration of the BCG live vaccine in infants exposed to anti-TNFs in utero have been reported. Infliximab, adalimumab, and probably also vedolizumab and ustekinumab treatments are considered compatible with breastfeeding, although minuscule amounts of these biologics have been detected in breast milk of treated nursing mothers. Based on the literature available, the benefits from breastfeeding while receiving infliximab [or any other anti-TNF] and at the same time adhering to national infant immunization programmes probably outweigh any hypothetical risk for the infant. Conclusions Vaccines appear to be effective in infants exposed to biologics in utero. Inactivated vaccines are probably safe, whereas live-attenuated vaccines should be avoided while the children have detectable levels of biological drugs. Vaccines [non-live and live] are probably safe in children breastfed by mothers treated with biologics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available